RPG Life Sciences Limited — PPTs, 29-04-2025: Investor Presentation

**Financial Highlights:**

RPG Life Sciences reported revenue from operations of ₹653.4 Cr, reflecting a 12.25% year-over-year growth. EBITDA rose to ₹172.3 Cr, resulting in a margin of 26.4%. Profit before tax (PBT) reached ₹150.3 Cr (23.0% margin), and profit after tax (PAT) grew to ₹111.6 Cr, with a PAT margin of 17.1%. The company maintains a debt-free status, highlighting strong cash flow management.

**Strategic Initiatives & Growth Drivers:**

RPG Life is enhancing its presence in domestic and international markets, focusing on specialty and chronic therapy segments. The company plans to invest approximately ₹140 Cr in capacity expansion to strengthen its product portfolio and aims to capture significant market share in immunosuppressants and high-value APIs.

**Business Developments:**

Recent strategies include digitization initiatives and comprehensive transformation projects to boost operational efficiencies. RPG Life is actively pursuing new product launches, supported by robust R&D efforts aligned with lifecycle management strategies.

**Market Position & Competitive Advantage:**

RPG Life holds a leading position in the Indian pharmaceutical market, recognized for strong brand equity and consistent growth. The company leverages expertise in immunosuppressants while expanding into newer categories and markets.

**Investor Implications:**

These updates indicate positive growth potential, underscored by sustainable profitability and strategic market expansions. Investors should monitor ongoing execution risks as RPG Life progresses with its transformation agenda and capitalizes on emerging market opportunities.